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EKSPRESI "INSULIN-LIKE GROWTH FACTORS" DAN RESEPTORNYA 
PADA PERINGKAT PRAIMPLANTASI DALAM TISU REPRODUKTIF 
MENCIT DIABETES 
 
 
 
 
ABSTRAK 
Kami menghipotesis bahawa embrio praimplantasi yang berkembang dalam 
persekitaran diabetes mengalami kekurangan faktor pertumbuhan tertentu. 
Tujuan utama kajian ini adalah untuk menentukan kesan diabetes ke atas 
perkembangan embrio praimplantasi mencit secara in vitro dan menganalisis 
ekspresi mRNA dan protein IGF-1, IGF-2, IGF-1R dan IGF-2R dalam tisu 
fallopio dan uterus mencit kontrol dan diabetes. Mencit ICR betina yang matang 
secara seksual berusia 6 hingga 8 minggu dijadikan diabetes dengan suntikan 
streptozotosin (200 mg/kg, intra peritoneum). Embrio normal dalam peringkat 2-
sel diperolehi daripada mencit kontrol dan diabetes yang diseperovulasi pada 
48 jam pasca rawatan korionik gonadotropin manusia (hCG). Embrio dikultur 
secara berasingan dan diperiksa di bawah mikroskop songsang selama 3 hari 
berturut-turut. Tisu fallopio dan uterus diperolehi daripada mencit kontrol dan 
diabetes yang disuperovulasi pada 48, 72 dan 96 jam pasca rawatan hCG. 
Kuantifikasi ekspresi mRNA menggunakan tindak balas polimerase masa nyata 
menggunakan piawai internal homologus yang dibangunkan secara spesifik 
untuk setiap gen. Ekspresi protein menggunakan pewarnaan imunohistokimia 
dijalankan ke atas tisu dan skor semikuantitatif dibuat berdasarkan sistem 5-
skala piawai. Bilangan embrio 2-sel yang diperolehi daripada mencit diabetes 
 xxv
adalah sangat berkurangan apabila dibanding dengan mencit kontrol. Walau 
bagaimanapun, tiada perbezaan yang signifikan dalam peratus perkembangan 
embrio 2-sel mencit kontrol dan diabetes. Ekspresi mRNA IGF-1 tisu fallopio 
dan uterus mencit diabetes rendah secara signifikan masing-masing pada 72 
dan 96 jam pasca rawatan hCG. Ekspresi mRNA IGF-1R kekal tinggi dalam tisu 
fallopio tetapi rendah secara signifikan dalam tisu uterus mencit diabetes pada 
96 jam pasca rawatan hCG. Ekspresi mRNA IGF-2 tisu fallopio mencit diabetes 
tinggi secara signifikan pada 48 dan 96 jam pasca rawatan hCG tetapi rendah 
secara signifikan dalam tisu uterus mencit diabetes pada 96 jam pasca rawatan 
hCG. Ekspresi mRNA IGF-2R tisu fallopio dan uterus mencit diabetes tinggi 
secara signifikan masing-masing pada 48 dan 96 jam, dan 48 jam pasca 
rawatan hCG. Untuk ekspresi protein, skor imunohistokimia IGF-1 dan IGF-1R 
berkurang secara signifikan dalam tisu fallopio pada 96 jam pasca rawatan 
hCG. Skor IGF-2 dan IGF-2R sebaliknya bertambah secara signifikan dalam 
tisu fallopio mencit diabetes masing-masing pada 48 dan 72 jam, dan pada 72 
jam pasca rawatan hCG. Walau bagaimanpun, tiada perbezaan skor yang 
signifikan bagi IGFs dan reseptornya dalam tisu uterus mencit kontrol dan 
diabetes. Sebagai kesimpulan, peratus perkembangan embrio 2-sel kepada 
blastosista adalah serupa di dalam mencit kontrol dan diabetes tetapi tidak 
dapat disahkan sama ada kualiti embrio tersebut sama atau tidak. Ekspresi 
mRNA dan protein IGFs dan reseptor masing-masing mengalami perubahan 
yang signifikan akibat kesan diabetes ibu, mencadangkan wujudnya peranan 
mereka dalam patogenesis embriopati diabetes. 
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THE EXPRESSION OF INSULIN-LIKE GROWTH FACTORS AND THEIR 
RECEPTORS AT PREIMPLANTATION STAGE IN REPRODUCTIVE 
TISSUES OF DIABETIC MOUSE  
 
 
 
 
ABSTRACT 
We hypothesized that the alteration in the expression of IGFs and their 
receptors may create an abnormal intrauterine environment thus affect embryos 
development. Therefore, the aims of the present study were to determine the 
effects of diabetes on in vitro development of mouse preimplantation embryos 
and to determine the mRNA and protein expression of IGF-1, IGF-2, IGF-1R 
and IGF-2R in the fallopian tube and uterine tissue of control and diabetic mice. 
Sexually mature female ICR mice of 6-8 weeks old were made diabetic by 
streptozotocin (200 mg/kg, intraperitoneal). The normal two-cell embryos were 
obtained from superovulated control and diabetic mice at 48 post-hCG 
treatment. Embryos were separately cultured and examined under an inverted 
microscope for 3 consecutive days. Fallopian tubes and uterine tissues were 
obtained from the superovulated control and diabetic mice at 48, 72 and 96 
hours post-hCG treatment. The mRNA expression was measured using Real-
time PCR using specifically developed homologous internal standards for each 
gene. Protein expression was measured by immunohistochemical staining and 
a semiquantitative scoring was performed using a standardized 5-scale system. 
The number of normal two-cell embryos obtained from diabetic mice was much 
reduced when compared to control mice. However, there was no significant 
 xxvi
i 
difference in the percentage of two-cell embryo development in control and 
diabetic mice. The mRNA expression of IGF-1 in the fallopian tube and uterus 
of diabetic mice was significantly low at 72 hours and 96 hours post-hCG 
treatment, respectively. The mRNA expression of IGF-1R remained high in the 
fallopian tube but was significantly low in the uterus of diabetic mice at 96 hours 
post-hCG treatment. The mRNA expression IGF-2 in the fallopian tube was 
significantly high at 48 and 96 hours post-hCG treatment but was significantly 
low in the uterus of diabetic mice at 96 hours post-hCG treatment. The mRNA 
expression of IGF-2R in the fallopian tube and uterus of diabetic mice was 
significantly high at 48 and 96 hours, and at 48 hours post-hCG treatments, 
respectively. For protein expression, the immunohistochemical scoring for both 
IGF-1 and IGF-1R was significantly decreased in the fallopian tube of diabetic 
mice at 96 hours post-hCG treatment. In contrast, the score for IGF-2 and IGF-
2R was significantly increased in the fallopian tube of diabetic mice at 48 and 72 
hours; and at 72 hours post-hCG treatment, respectively. However, there was 
no significant difference in the score of IGFs and their receptors in the uterus of 
control and diabetic mice. In conclusion, the percentage of the two-cell stage 
embryos which developed to blastocysts was similar in control and diabetic 
groups but whether the quality of these embryos were the same could not be 
confirmed. Both the mRNA and protein expression of IGFs and their receptors 
were significantly altered by maternal diabetes, which suggest their role in the 
pathogenesis of diabetic embryopathy. 
 
 
 
 
 
 
 
CHAPTER ONE 
GENERAL INTRODUCTION 
 
 
 
 
1.1 PHYSIOLOGY OF PREIMPLANTATION EMBRYO DEVELOPMENT 
 
1.1.1 Proliferation and differentiation of preimplantation embryo 
Fertilization of the mouse ovum by sperm occurs in the ampullary region 
of the fallopian tube. Subsequent development occurs as the embryo moves 
down the fallopian tube and into the uterus over a period of about four days in 
mice, as compared to five and seven days in rats and humans, respectively 
(Figure 1.1). Approximately 24 hours after fertilization, the embryo undergoes 
relatively synchronous cell division resulting in the formation of two cells or 
blastomers. There are no junctions established between the individual cells, 
which are held together by ionic attractions on the opposing plasma membranes 
(Chavez, 1984). The cells are constrained within a physical shell, the zona 
pellucida, which is a matrix of four glycoproteins (Wassarman and Mortillo, 
1991). During this period, each blastomere is totipotent, retaining the capacity to 
form a complete fetus. Further mitotic divisions occur asynchronously at 
progressively shorter intervals so that from the eight-cell stage onwards, one 
cell cycle is approximately six hours. At the eight-cell stage, generation of two 
distinct lineages commences with the process of compaction when individual 
blastomers polarize, become epithelial-like and flatten on each other, 
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  Figure 1.1 Development of the preimplantation embryo in mice from 
 embryonic Day 1 through Day 4  
 (Adapted from Hogan et al., 1986) 
 
The fertilization takes place in the ampullary region of the fallopian tube and the 
developing embryo traverse down to the site of implantation in the uterine cavity. 
maximising cell contact and forming tight and gap junctions (Ducibella et al., 
1977; Magnuson and Epstein, 1981; Chavez, 1984; Fleming et al., 1992). This 
compacted morula stage coincides with the arrival of the embryo at the utero-
tubal junction. In the compacted morula, fluid is transported across the newly 
formed epithelium to form a blastocoel and at this point the embryo is referred 
to as a blastocyst. At this stage, two distinct cell populations can be recognized 
(Johnson, 1981). The eccentrically placed inner cell mass (ICM) eventually 
forms the embryo proper and some extraembryonic tissues. The trophectoderm 
(TE), which is a single epithelial layer of flattened cells surrounding the 
blastocoel and ICM, establishes the foci of adhesion with the uterine epithelium 
and gives rise to the fetal component of the placenta (Hogan et al., 1986). 
 
1.1.2 Metabolic activity of preimplantation embryo 
Mouse oocyte and zygote have an absolute requirement for pyruvate 
(Biggers et al., 1967); i.e. glucose cannot support early embryo development 
until the eight-cell stage (Biggers, 1971). From the two-cell to the blastocyst 
stage, the embryos experience an increase in the tricarboxylic acid (TCA) cycle 
metabolites and a dramatic increase in fructose 1, 6-biphosphate (FBP). The 
dramatic switch from a dependence on the TCA to a metabolism based on 
glycolysis occurs at the time of compaction. The only source of adenosine 
triphosphate (ATP) for the preimplantation embryo would be conversion of 
glucose to pyruvate and lactate via glycolysis. 
 
The blastocyst stage marks a new peak in cellular proliferation and 
growth. These changes create new biosynthetic demands on the embryos. 
Maintenance of a high rate of glycolysis is important for providing a “dynamic 
buffer” of metabolic intermediates for the biosynthesis of macromolecules 
(Newsholme and Newsholme, 1989) and increasing amount of glucose are 
converted to lactate at this stage in humans and rodents (Leese and Barton, 
1984). Interspecies variations in the rate of glycolysis have been reported, 
higher in human blastocysts (Leese et al., 1993) and lower in mouse 
blastocysts (Leese, 1991) compared to rat embryos. 
 
Blastocysts are actively engaged in the uptake and metabolism of 
maternally derived nutrients such as glucose (Leese, 1991). The major site of 
uptake regulation is likely to be the system of facilitative glucose transporters 
(GLUT) situated at the basolateral surface of the TE in mouse blastocysts 
(Aghayan et al., 1992).  
 
1.1.3 Influence of maternal factors on preimplantation embryo 
development 
Although the activation of the embryonic genome provides the conceptus 
with a number of vital developmental signals (Kidder, 1992; Schultz and 
Heyner, 1992), its progression through the preimplantation period is also 
influenced by maternal factors present in the oviductal and uterine environment.  
 
Biggers (1981) proposed a theoretical model summarizing the 
physiological processes that influence the microenvironment of the 
preimplantation embryo. The composition of the microenvironment is 
determined by several transport mechanisms: between the embryo and the 
secretions in which it is bathed, between the fallopian tube and uterus and the 
bathing secretions and further mixing is produced as the secretions flow up and 
down the reproductive tract as shown in Figure 1.2. 
 
Maternally-derived nutrients/factors can either be transudates from the 
maternal circulation such as glucose (Leese et al., 1979, Wales and 
Edirisinghe, 1989; Gonzalez et al., 1994) and insulin (Heyner et al., 1989; Smith 
et al., 1993), or secretions by various uterine cells into the lumen such as 
growth factors (Pollard, 1990; Song et al., 2000) and cytokines (Pampfer et al., 
1991; Robertson et al., 2001) during the preimplantation period.  
 
1.2 DIABETIC PREGNANCY 
The association between maternal diabetes and the increased risk of 
congenital malformations has a long history and was first reported by LeCorche 
(1885). It is generally accepted that congenital malformations are the leading 
cause of death in the offspring of diabetic women (Kitzmiller et al., 1978). The 
incidence of congenital malformations is approximately 6 to 9% in diabetic 
pregnancies, which is three- to four-fold higher than in the general population, 
and accounts for 33 to 66% of perinatal deaths (Reece and Hobbins, 1986). 
The congenital malformations most commonly associated with maternal 
diabetes are listed in Table 1.1 (Reece and Hobbins, 1986). However, none of 
the reported congenital malformations is pathognomonic for the diagnosis of 
diabetic embryopathy. 
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Figure 1.2 A theoretical model summarising the physiological processes that 
influence the microenvironment of the preimplantation embryo 
(Adapted from Biggers, 1981). 
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1.3 DEFINITION OF “DIABETIC EMBRYOPATHY” 
The term “embryopathia diabetica” was coined by Mayer (1952) and was 
later replaced by the term “diabetic embryopathy” (Passarge and Lenz, 1966). 
The concept of diabetic embryopathy initially encompassed the long-recognized 
newborn features such as macrosomia and organomegaly but was later 
broadened to include congenital malformations (Mayer and Camara, 1964). 
Presently, the same concept was separated into two different entities, diabetic 
embryopathy and diabetic fetopathy. Diabetic embryopathy occurs during 
embryogenesis, mainly from the end of blastogenesis until the period of 
organogenesis (between the 3rd and 7th week of gestation) and is associated 
with congenital malformations (Kousseff, 1999). In contrast, diabetic fetopathy 
occurs during fetal development, after the 10th week of gestation, and is not 
associated with malformations (Kousseff, 1999). Occasionally, diabetic 
embryopathy is associated with diabetic fetopathy. However, these two entities, 
both induced by maternal diabetes mellitus, have different windows of 
vulnerability and perhaps, different pathogenesis. 
 
1.4 AETIOLOGICAL FACTORS ASSOCIATED WITH DIABETIC 
EMBRYOPATHY 
It has been suggested that the absence of a specific malformation 
pattern for diabetic embryopathy signals the presence of several aetiological 
factors and mechanisms in diabetic pregnancy (Khoury et al., 1989). Likewise, 
the number of different teratogenic agents identified indicates that diabetic 
embryopathy is of complex aetiology (Sadler et al., 1989; Zusman et al., 1989; 
Buchanan et al., 1994). 
1.4.1 Maternal Hyperglycemia 
Hyperglycemia-induced teratogenic effects have been demonstrated in 
animal studies both in vivo and in vitro (Cockroft and Coppola, 1977; Baker et 
al., 1981; Horton and Sadler, 1983; Kalter and Warkany, 1983a & 1983b; 
Freinkel et al., 1986; Reece and Hobbins, 1986). The percentage of congenital 
malformations correlated with blood glucose levels (Reece et al., 1985) and 
glycosylated hemoglobin levels (Rose et al., 1988). 
 
The period and time of exposure to hyperglycemia as well as the level of 
hyperglycemia are all important for dysmorphogenesis to occur. The critical 
period of exposure to hyperglycemia is during organogenesis, which is 
considered to be between days 9.5 to 11.5 in rats and 8.0 to 9.6 in mice 
(Freinkel, 1988), corresponding to the first 5 or 6 weeks of human pregnancy. A 
minimum exposure time of two or more hours is needed to induce these 
malformations. A 20% malformation rate was induced at glucose levels that 
were approximately two-fold above normal concentrations; an almost 50% 
malformation rate was seen at glucose levels three-fold above normal 
concentrations; and approximately 100% rate at six times above normal 
concentrations (Reece et al., 1985).  
 
Maternal hyperglycemia adversely affects not only the postimplantation 
embryos but also preimplantation progression from one-cell to the blastocyst 
stage in a streptozotocin (STZ)-induced or a non-obese diabetic (NOD) mouse 
model (Diamond et al., 1989; Moley et al., 1991 & 1994). In the NOD model at 
96 hours after superovulation and mating, only 20% of the recovered embryos 
reached blastocyst stage in the diabetic compared to 90% among the non-
diabetic. This developmental delay is reversible by treating the mothers with 
insulin before superovulation and mating and during the first 96 hours of 
gestation. This early preimplantation delay may be manifested later in gestation 
as fetal loss, early growth delay or congenital malformation. There is now 
convincing evidence that severe developmental anomalies leading to fetal 
resorption or malformation can occur as a consequence of subtle damage 
inflicted to the embryos before or at the time of implantation (Rutledge, 1997). 
 
The mechanism of hyperglycemia-induced congenital anomalies remains 
unclear. Hyperglycemia-induced reduction in GLUT has been proposed to be 
one of the possible mechanisms. A paradoxical reaction to hyperglycemia has 
been demonstrated in preimplantation embryos (Moley, 1999). In embryos of 
diabetic mice, a pronounced intracellular hypoglycemia was found despite 
maternal hyperglycemia (Moley et al., 1998b). The decreased intracellular 
glucose concentration was associated with decreased GLUT namely, GLUT-1, 
GLUT-2 and GLUT-3 isoforms; both at the protein and mRNA levels (Moley et 
al., 1998b).  
 
Reduced availability of glucose associated with decreased GLUT in 
diabetic embryos, results in significantly lower FBP and higher pyruvate, 
indicating decreased glycolysis and increased pyruvate uptake by the embryos, 
respectively. The glycolytic changes lead to dysfunction of the outer 
mitochondrial membrane and subsequently trigger the apoptotic cascade (Chi 
et al., 2002). 
The decrease in GLUT especially GLUT-1 and -3 isoforms also explains 
the elevated extracellular dehydroascorbate (DHA) and reduced intracellular 
ascorbic acid (Rumsey et al., 1997) related to hyperglycemia as described 
previously (Ely, 1981). Ely (1981) proposed that reduced intracellular ascorbic 
acid resulted in decreased hexose monophosphate shunt activity (DeChatelet et 
al., 1972), which might suppress deoxyribonucleic acid (DNA) synthesis as 
shown in Figure 1.3. Reduced DNA synthesis may slow cell division, leading to 
impaired cell proliferation or anomalies. It has also been suggested that 
elevated extracellular DHA may inhibit mitosis or cell proliferation (Edgar, 1970).  
 
This decrease in intracellular glucose concentration leads to a lower cell 
number in the ICM, either by increased apoptotic rate (Pampfer et al., 1997b; 
Moley et al., 1998a), or by diminished proliferation of these cells (Pampfer et al., 
1990). Decrease in glucose transport and metabolism is not only related to 
progressive decrease in embryo viability but served as important regulatory 
points in the early apoptotic cascade (Johnson et al., 1996; Li et al., 1998; Shim 
et al., 1998; Bialik et al., 1999, Lin et al., 2000). Maternal hyperglycemia, 
moreover, can cause direct disruption of the highly regulated gene program that 
controls the expression pattern of crucial developmental determinants during 
early embryogenesis, including apoptosis (Phelan et al., 1997; Cai et al., 1998; 
Moley et al., 1998a; Pampfer et al., 2001).  
 
Three cell death paradigms that are linked to decreased GLUT include, 
(i) induction of ATP depletion and stimulation of the mitochondrial death 
cascade or (ii) induction of oxidative stress and triggering of Bax-associated 
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                    (Adapted from Ely, 1981) 
events including the c-Jun N-terminal kinase (JNK) and mitogen-activated 
protein kinase (MAPK) signalling pathways or (iii) regulation of expression of the 
gene encoding hypoxia-inducible factor 1 (HIF-1) and the stabilization of p53 
by HIF-1 binding, leading to an increase in p53-associated apoptosis and, in 
turn, increased expression of Bax, and thus exaggerated apoptosis within 
blastocysts during glucose deprivation (Chi et al., 2000; Moley and Mueckler, 
2000; Keim et al., 2001).  
 
The outcome of apoptosis during preimplantation stage will depend on 
the percentage of cell death, if more than 60% of ICM undergo cell death, the 
pregnancy may result in fetal loss and resorption. However, the death of fewer 
cells (e.g. 40-45%) can result in either fetal resorption or malformation if this cell 
death involves key progenitor cells in development (Tam, 1988; Moley, 2001). 
 
Another possible mechanism of hyperglycemia-induced congenital 
anomalies that has been put forward is related to dysregulation in the uterine 
cytokine secretion (Pampfer, 2001). Diabetes-induced modifications in the 
oviductal and uterine concentrations of nutrients (such as increased glucose 
levels), hormones (such as decreased insulin levels), growth factors, and 
cytokines (increased local synthesis of inhibitory factors or decreased local 
synthesis of stimulatory factors) are likely to elicit alterations in embryo 
development before implantation and organogenesis. 
 
Studies in STZ- and alloxan-treated diabetic mice exhibit an increased 
amount of tumour necrosis factor- (TNF-) messenger ribonucleic acid 
(mRNA) and protein in the uterus and placenta of diabetic mice (Pampfer et al., 
1995; Flein et al., 2001) as well as a marked reduction in pregnancy rate and a 
high incidence of litters with severely malformed fetuses (Torchinsky et al., 
1997, Machado et al., 2001). In addition, overexpression and excessive 
secretion of TNF-α by uterine cells in diabetic pregnancy may induce a 
decrease in cell number of the ICM as reported in an earlier study (Pampfer et 
al., 1997b; Wuu et al., 1999).  
 
TNF- acts in a cell type- and stimulus-dependent manner, to generate 
apoptotic-signalling pathways (Baud and Karin, 2001; Gupta, 2001). The 
apoptotic action of TNF- could occur mainly through its binding to the type 1 
receptor TNF-, followed by the activation of caspase 8 (Slee et al., 1999; Mohr 
et al., 2002; Torchinsky et al., 2003), which is considered to be among the main 
mediators of apoptosis (Baud and Karin, 2001; Gupta, 2001). The apoptotic 
action of TNF- could be mediated through interleukin-1ß (IL-1ß) secreted by 
macrophages (Pampfer et al., 1999) localized at the subepithelial region of the 
uterine stroma (Takacs et al., 1988). 
 
The mechanism of hyperglycemia-induced IL-1ß secretion has been 
proposed to be via the formation and interaction of advanced glycation end 
products, AGE (Vlassara et al., 1988). Macrophages have a receptor that 
recognizes the AGE moiety and mediates the uptake and degradation of AGE 
proteins. This removal process is associated with the production and secretion 
of TNF- and IL-1. The localized release and action of these cytokines may play 
